Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis

被引:0
作者
Qing An
Zhihao Liu
机构
[1] Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University,Institute for Health Education
[2] Jiangsu Provincial Center for Disease Control and Prevention,undefined
来源
BMC Cancer | / 19卷
关键词
Advanced melanoma; PD-1/L1 blockade; CTLA-4 blockade; BRAF inhibitor; MEK inhibitor;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 237 条
[41]  
Stroiakovski D(2017)Systemic therapy for previously untreated advanced BRAF-mutated melanoma: a systematic review and network meta-analysis of randomized clinical trials JAMA Oncol 3 366-e381
[42]  
Cipriani A(2015)Pembrolizumab versus Ipilimumab in Advanced Melanoma N Engl J Med 372 2521-1246
[43]  
Higgins JP(2013)Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 14 e60-253
[44]  
Geddes JR(2014)Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 15 e371-3060
[45]  
Salanti G(2011)Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol 29 1239-undefined
[46]  
Salanti G(2015)PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials Pigment Cell Melanoma Res 28 245-undefined
[47]  
Jansen JP(2015)Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites Clin Cancer Res 21 3052-undefined
[48]  
Crawford B(undefined)undefined undefined undefined undefined-undefined
[49]  
Bergman G(undefined)undefined undefined undefined undefined-undefined
[50]  
Stam W(undefined)undefined undefined undefined undefined-undefined